NCT06533332View on ClinicalTrials.gov

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid TumorMetastatic Breast CancerMetastatic Ovarian CancerMetastatic Endometrial CancerMetastatic Liver CancerMetastatic Pancreatic Cancer
Interventions
DRUG

ERX-315

Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.

Trial Locations (4)

2010

RECRUITING

The Kinghorn Cancer Center, Sydney

2109

RECRUITING

Macquarie University Health, Ryde

5000

RECRUITING

Cancer Research SA, Adelaide

5037

RECRUITING

Icon Cancer Centre Adelaide, Adelaide

All Listed Sponsors
lead

EtiraRx Australia Pty Ltd

OTHER

NCT06533332 - A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter